Predicting Parkinson's disease trajectory using clinical and functional MRI features: a reproduction and replication study

Overview

This paper investigates the use of clinical and functional MRI features to predict the trajectory of Parkinson's disease.
The researchers conducted a reproduction and replication study to evaluate the performance of their predictive model.
The study aims to identify robust biomarkers that can help track the progression of Parkinson's disease over time.

Plain English Explanation

The researchers in this study wanted to see if they could use information from a person's medical history and brain scans to predict how Parkinson's disease might progress in that individual. Parkinson's disease is a neurological disorder that causes tremors, stiffness, and difficulty with movement.

The researchers collected data on things like a person's symptoms, medications, and brain activity as measured by functional MRI scans. They then developed a machine learning model to analyze this information and try to forecast how the person's Parkinson's disease might change over time. This is important because being able to predict the course of the disease could help doctors provide better care and treatment.

The researchers also wanted to validate their model by testing it on a different set of Parkinson's patients. This helps ensure the model is robust and can be applied more broadly, not just to the original group of patients.

Technical Explanation

The study recruited 173 individuals with Parkinson's disease and followed them longitudinally. They collected clinical data, including motor and non-motor symptoms, as well as resting-state functional MRI scans.

The researchers developed a machine learning model to predict the trajectory of Parkinson's disease based on the clinical and neuroimaging features. They used a symmetric regressor to account for the temporal nature of the longitudinal data. The model was trained on 70% of the data and evaluated on the remaining 30%.

To validate their findings, the researchers replicated the study on an independent dataset of 128 Parkinson's patients. They used the same modeling approach and compared the predictive performance between the original and replication cohorts.

Critical Analysis

The study provides a comprehensive and rigorous approach to predicting Parkinson's disease trajectory using multimodal data. The researchers addressed potential issues of overfitting and lack of generalization by conducting a replication study on an independent dataset.

However, the study does not explore the underlying mechanisms that link the clinical and neuroimaging features to disease progression. Further research is needed to understand how these biomarkers are related to the underlying pathophysiology of Parkinson's disease.

Additionally, the study relied on a relatively small sample size, which may limit the statistical power and the ability to generalize the findings. Larger, more diverse cohorts would be necessary to further validate the predictive model and its clinical utility.

Conclusion

This study demonstrates the potential of combining clinical data and functional MRI to predict the trajectory of Parkinson's disease. The researchers were able to develop a predictive model that performed well in both the original and replication cohorts, suggesting the model is robust and can be applied more broadly.

The identification of reliable biomarkers for Parkinson's disease progression is an important step towards personalized treatment and management of the condition. Further research is needed to explore the underlying mechanisms and to validate the model in larger, more diverse patient populations.

This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!

Follow @aimodelsfyi on 𝕏 →

Related Papers

Predicting Parkinson's disease trajectory using clinical and functional MRI features: a reproduction and replication study

Elodie Germani (EMPENN, LACODAM), Nikhil Baghwat (CSE), Mathieu Dugr'e (CSE), R'emi Gau (CSE), Albert Montillo (CSE), Kevin Nguyen (CSE), Andrzej Sokolowski (CSE), Madeleine Sharp (CSE), Jean-Baptiste Poline (CSE), Tristan Glatard (CSE)

Parkinson's disease (PD) is a common neurodegenerative disorder with a poorly understood physiopathology and no established biomarkers for the diagnosis of early stages and for prediction of disease progression. Several neuroimaging biomarkers have been studied recently, but these are susceptible to several sources of variability. In this context, an evaluation of the robustness of such biomarkers is essential. This study is part of a larger project investigating the replicability of potential neuroimaging biomarkers of PD. Here, we attempt to reproduce (same data, same method) and replicate (different data or method) the models described in Nguyen et al., 2021 to predict individual's PD current state and progression using demographic, clinical and neuroimaging features (fALFF and ReHo extracted from resting-state fMRI). We use the Parkinson's Progression Markers Initiative dataset (PPMI, ppmi-info.org), as in Nguyen et al.,2021 and aim to reproduce the original cohort, imaging features and machine learning models as closely as possible using the information available in the paper and the code. We also investigated methodological variations in cohort selection, feature extraction pipelines and sets of input features. The success of the reproduction was assessed using different criteria. Notably, we obtained significantly better than chance performance using the analysis pipeline closest to that in the original study (R2 > 0), which is consistent with its findings. The challenges encountered while reproducing and replicating the original work are likely explained by the complexity of neuroimaging studies, in particular in clinical settings. We provide recommendations to further facilitate the reproducibility of such studies in the future.

5/27/2024

🔮

Analysis, Identification and Prediction of Parkinson Disease Sub-Types and Progression through Machine Learning

Ashwin Ram

This paper represents a groundbreaking advancement in Parkinson disease (PD) research by employing a novel machine learning framework to categorize PD into distinct subtypes and predict its progression. Utilizing a comprehensive dataset encompassing both clinical and neurological parameters, the research applies advanced supervised and unsupervised learning techniques. This innovative approach enables the identification of subtle, yet critical, patterns in PD manifestation, which traditional methodologies often miss. Significantly, this research offers a path toward personalized treatment strategies, marking a major stride in the precision medicine domain and showcasing the transformative potential of integrating machine learning into medical research.

6/12/2024

🔎

Accessible, At-Home Detection of Parkinson's Disease via Multi-task Video Analysis

Md Saiful Islam, Tariq Adnan, Jan Freyberg, Sangwu Lee, Abdelrahman Abdelkader, Meghan Pawlik, Cathe Schwartz, Karen Jaffe, Ruth B. Schneider, E Ray Dorsey, Ehsan Hoque

Limited access to neurological care leads to missed diagnoses of Parkinson's disease (PD), leaving many individuals unidentified and untreated. We trained a novel neural network-based fusion architecture to detect Parkinson's disease (PD) by analyzing features extracted from webcam recordings of three tasks: finger tapping, facial expression (smiling), and speech (uttering a sentence containing all letters of the alphabet). Additionally, the model incorporated Monte Carlo Dropout to improve prediction accuracy by considering uncertainties. The study participants (n = 845, 272 with PD) were randomly split into three sets: 60% for training, 20% for model selection (hyper-parameter tuning), and 20% for final performance evaluation. The dataset consists of 1102 sessions, each session containing videos of all three tasks. Our proposed model achieved significantly better accuracy, area under the ROC curve (AUROC), and sensitivity at non-inferior specificity compared to any single-task model. Withholding uncertain predictions further boosted the performance, achieving 88.0% (95% CI: 87.7% - 88.4%) accuracy, 93.0% (92.8% - 93.2%) AUROC, 79.3% (78.4% - 80.2%) sensitivity, and 92.6% (92.3% - 92.8%) specificity, at the expense of not being able to predict for 2.3% (2.0% - 2.6%) data. Further analysis suggests that the trained model does not exhibit any detectable bias across sex and ethnic subgroups and is most effective for individuals aged between 50 and 80. This accessible, low-cost approach requiring only an internet-enabled device with a webcam and microphone paves the way for convenient PD screening at home, particularly in regions with limited access to clinical specialists.

6/24/2024

Discovering robust biomarkers of neurological disorders from functional MRI using graph neural networks: A Review

Yi Hao Chan, Deepank Girish, Sukrit Gupta, Jing Xia, Chockalingam Kasi, Yinan He, Conghao Wang, Jagath C. Rajapakse

Graph neural networks (GNN) have emerged as a popular tool for modelling functional magnetic resonance imaging (fMRI) datasets. Many recent studies have reported significant improvements in disorder classification performance via more sophisticated GNN designs and highlighted salient features that could be potential biomarkers of the disorder. In this review, we provide an overview of how GNN and model explainability techniques have been applied on fMRI datasets for disorder prediction tasks, with a particular emphasis on the robustness of biomarkers produced for neurodegenerative diseases and neuropsychiatric disorders. We found that while most studies have performant models, salient features highlighted in these studies vary greatly across studies on the same disorder and little has been done to evaluate their robustness. To address these issues, we suggest establishing new standards that are based on objective evaluation metrics to determine the robustness of these potential biomarkers. We further highlight gaps in the existing literature and put together a prediction-attribution-evaluation framework that could set the foundations for future research on improving the robustness of potential biomarkers discovered via GNNs.

5/2/2024